Company type | Subsidiary of National Dairy Development Board |
---|---|
Industry | Biotechnology |
Headquarters | Hyderabad, India |
Key people | Dr. K. Anand Kumar (Managing Director) |
Website | www |
Indian Immunologicals Limited (IIL) is a subsidiary of the National Dairy Development Board. It is based in Hyderabad, Telangana, India.[1] IIL is registered in India as a Public Limited Company under the Companies Act, 1956 (Ministry of Corporate Affairs – MCA Services),[2] It was established in 1982 by the National Dairy Development Board.[3][4]
It is noted for developing veterinary and human vaccines for foot-and-mouth disease, rabies, bacterial vaccines, canine vaccines, hepatitis, measles, MMR and DPT.
IIL is a major supplier of DPT, TT and hepatitis B vaccines to India's large Universal Immunization Programme.[5][6] IIL has three vaccine manufacturing facilities in India. The Gachibowli-Hyderabad facility is engaged in the production of vaccines, while the Karakapatla-Hyderabad facility produces animal health formulations and human vaccines. IIL's facility in Ooty exclusively produces human anti-rabies vaccine, "Abhayrab". Pristine Biologicals Ltd is IIL's subsidiary in New Zealand and is involved in the production of serum used in the manufacture of vaccines.[7] Indian Immunologicals, IIL, on 25 November 2023 launched the measles and rubella vaccine 'Mabella' for children. A live-attenuated MR vaccine developed in partnership with Polyvac Institute of Vietnam was launched as part of the 25th celebrations of the IIL division Human Biologicals Institute (HBI) in Udhagamandalam (Ooty), Tamil Nadu.